Andrew Obenshain, bluebird bio CEO
Bluebird joins the layoff flock to reality as gene therapy biotech sheds staff to save itself
Bluebird bio is laying off about 30% of its workforce to save itself before the FDA decides the fate of two of its gene therapies in August and September and plans to file for a third approval in the first quarter of next year.
The dire situation came into clear view earlier this year when bluebird said in a quarterly filing its cash problems “raise substantial doubt regarding its ability to continue as a going concern” in the coming year. The CFO resigned the same day.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters